The U.S. Food and Drug Administration (FDA) is tightening restrictions on a gene therapy used to treat Duchenne muscular dystrophy after two teenagers died from liver failure linked to the medication. The FDA decision limits the use of Elevidys, made by Sarepta Therapeutics, to boys who are 4 years and older who can still walk,… read on > read on >


















-300x200.jpeg)
